Aardvark Therapeutics
Develops gut-restricted oral programs for hunger-associated conditions and obesity.
$6.14
After-hours close+0.36 (+6.23%)
At close$5.78(−12.69%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.74 | — | — |
| Aug 2026 | −$0.87 | −$0.66 | +24.1% |
| Aug 2026 | −$0.87 | −$0.66 | +24.5% |
| May 2026 | −$0.87 | −$0.99 | −14.0% |
| Mar 2026 | −$0.83 | −$0.81 | +2.1% |
The latest year is open to everyone — the 9 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Sep 2024 | |||
| Jun 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.74 | — | — | — | — | — |
| Aug 12, 2026 | −$0.87 | −$0.66 | +24.1% | — | — | — |
| Aug 11, 2026 | −$0.87 | −$0.66 | +24.5% | — | — | — |
| May 7, 2026 | −$0.87 | −$0.99 | −14.0% | — | — | — |
| Mar 23, 2026 | −$0.83 | −$0.81 | +2.1% | — | — | — |
The latest year is open to everyone — the 9 quarters behind it read with an account. Sign in | ||||||
| Nov 13, 2025 | ||||||
| Aug 13, 2025 | ||||||
| May 14, 2025 | ||||||
| Feb 26, 2025 | ||||||
| Sep 30, 2024 | ||||||
| Jun 30, 2024 | ||||||
| Mar 31, 2024 | ||||||
| Dec 31, 2023 | ||||||
| Sep 30, 2023 | ||||||